237 related articles for article (PubMed ID: 27435001)
1. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
[TBL] [Abstract][Full Text] [Related]
2. An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity against Colorectal Cancer.
Schmied BJ; Riegg F; Zekri L; Grosse-Hovest L; Bühring HJ; Jung G; Salih HR
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181683
[TBL] [Abstract][Full Text] [Related]
3. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia.
Riegg F; Lutz MS; Schmied BJ; Heitmann JS; Queudeville M; Lang P; Jung G; Salih HR; Märklin M
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915811
[TBL] [Abstract][Full Text] [Related]
4. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
5. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
6. Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.
Stefańczyk SA; Hagelstein I; Lutz MS; Müller S; Holzmayer SJ; Jarjour G; Zekri L; Heitmann JS; Salih HR; Märklin M
Blood Cancer J; 2024 Apr; 14(1):67. PubMed ID: 38637557
[TBL] [Abstract][Full Text] [Related]
7. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
[TBL] [Abstract][Full Text] [Related]
8. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
9. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
10. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
11. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R; Kössl C; Bucci D; Lucas DM; Yu J; Caligiuri MA; Blum W; Adam PJ; Borges E; Rueter B; Heider KH; Marcucci G; Muthusamy N
Blood; 2016 Jun; 127(23):2879-89. PubMed ID: 27013443
[TBL] [Abstract][Full Text] [Related]
12. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
13. Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody.
Schmied BJ; Lutz MS; Riegg F; Zekri L; Heitmann JS; Bühring HJ; Jung G; Salih HR
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817795
[TBL] [Abstract][Full Text] [Related]
14. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
15. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M
Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689
[TBL] [Abstract][Full Text] [Related]
17. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
19. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody.
Lee HR; Son CH; Koh EK; Bae JH; Kang CD; Yang K; Park YS
Sci Rep; 2017 Sep; 7(1):11075. PubMed ID: 28894091
[TBL] [Abstract][Full Text] [Related]
20. Activation of cloned human natural killer cells via Fc gamma RIII.
Werfel T; Uciechowski P; Tetteroo PA; Kurrle R; Deicher H; Schmidt RE
J Immunol; 1989 Feb; 142(4):1102-6. PubMed ID: 2464637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
